Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2b, Open Label, Randomized, Parallel-Group, Multi-Center Study to Evaluate the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered With or Without Routine Infant Vaccinations to Healthy Infants According to Different Immunization Schedules.

NCT00721396 is registered in ClinicalTrials.gov with Novartis Vaccines as lead sponsor.

NCT NCT00721396
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00721396 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2b, Open Label, Randomized, Parallel-Group, Multi-Center Study to Evaluate the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered With or Without Routine Infant Vaccinations to Healthy Infants According to Different Immunization Schedules.
Lead sponsor
Novartis Vaccines
Phase
Phase 2
Overall status
Completed
Start date
August 31, 2008
Completion date
July 31, 2010
Enrollment
1,885 (actual)
Sites
60

Conditions

As the registry lists them; a condition with its own page is linked.

meningococcal infections